论文部分内容阅读
2001年,针对我国医药生产、批发的小企业数量过多,正常的医药生产经营秩序受到严重干扰的情况,政府相关部门做出了“总量调控淘汰落后”的指示。受此影响,国内制药企业上演了一场淘汰,兼并大战,大量中小药企不是遭到淘汰,就是被兼并,广药集团、哈药集团等几家大型药企不断发展壮大,成为行业内的巨头。在生存的压力下,实力稍逊一筹的江中药业开始寻求新的增长点,使自己在该行业站稳脚跟,并不断壮大。为了提升销量,江中药业想尽了办法,加大广告投入,不
In 2001, in response to the serious interference in the order of the pharmaceutical production and operation in the country where the number of small and medium-sized enterprises engaged in pharmaceutical production and wholesale was too large, the relevant government departments made the directive of “eliminating the backwardness of the general regulation and control”. Affected by this, the domestic pharmaceutical companies staged a phase-out, mergers and acquisitions, a large number of small and medium-sized pharmaceutical companies have not been eliminated, is being merged, Guangzhou Pharmaceutical Group, Harbin Pharmaceutical Group, several large pharmaceutical companies continue to grow and develop, become the industry Giant. Under the pressure of survival, Jiangzhong Pharmaceutical Co., Ltd., which is inferior in strength, began to seek new growth points and gained a firm foothold in the industry. In order to enhance sales, Jiangzhong medicine tried every means to increase advertising input, no